Sugiyama Yoichi, Morifuji Masahiko, Murakami Yoshiaki, Uemura Kenichiro, Hayashidani Yasuo, Sudo Atsushi, Hashimoto Yasushi, Sueda Taijiro
Dept. of Surgery, Division of Clinical Medical Science, Graduate School of Biomedical Sciences, Hiroshima University.
Gan To Kagaku Ryoho. 2006 Jun;33(6):795-8.
A 70-year-old man suffering from advanced esophageal cancer (Stage II) underwent subtotal esophagectomy in December 2000. He then had postoperative chemotherapy, called low-dose FP, and was followed in an ambulatory setting. In December 2003, he was diagnosed as a recurrence of esophageal cancer with multiple liver metastases and upper mediastinum lymph node, so he was treated by combined chemotherapy consisting of TS-1 and docetaxel as a second-line chemotherapy. After 3 courses of this therapy, CT scan showed that the size of liver and lymph node metastases was reduced and the effect of this therapy was PR. PR continued for about 6 months. This chemotherapy made it possible to treat liver and lymph node metastasis in an ambulatory setting. It is conceivable that this combination chemotherapy might be a promising regimen for a short period.
一名70岁患有晚期食管癌(II期)的男性于2000年12月接受了食管次全切除术。随后他接受了名为低剂量FP的术后化疗,并在门诊接受随访。2003年12月,他被诊断为食管癌复发,伴有多处肝转移和上纵隔淋巴结转移,因此作为二线化疗接受了由替吉奥(TS-1)和多西他赛组成的联合化疗。经过3个疗程的这种治疗后,CT扫描显示肝和淋巴结转移灶的大小减小,该治疗效果为部分缓解(PR)。PR持续了约6个月。这种化疗使得在门诊环境中治疗肝和淋巴结转移成为可能。可以想象,这种联合化疗可能是短期内一种有前景的治疗方案。